“ Welcome to OpenDELClub ”

HitGen OpenDELClub

A platform for researchers and professionals interested in  DNA-encoded library (DEL) technology and drug discovery, providing a space for knowledge exchange, innovation, and partnership.

Latest Progress of DEL

  • News

    ESG | HitGen Releases Its Inaugural Sustainability Report

    CHENGDU, China, July 4, 2025 – Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH) today announced the release of its inaugural sustainability report, aiming to present the company's philosophies and policies in environmental, social, and governance ("ESG") areas, as well as its sustainability practices and performance in the year of 2024, systematically addressing stakeholders' concerns.  Dr. Jin Li, Chairman of the Board and CEO of HitGen Inc., commented: "It is my great pleasure to share with you HitGen's inaugural Sustainability Report. As an enterprise at the forefront of drug discovery research, HitGen aspires to advance innovative drug discovery for the healthcare industry. We are committed to original innovation of drug discovery, continuously delivering new molecular entities to the industry, and contributing to improved human health. In 2024, while continuing to enhance our competitiveness in biopharmaceutical R&D services, we systematically integrated sustainability concepts throughout our operational processes, striving to achieve synergistic development in governance efficiency, low-carbon transmission, talent development, and community well-being."    Sustainable Corporate GovernanceA robust governance framework and capabilities form the solid foundation for sustainable corporate development. HitGen continuously enhances its governance structure to ensure transparent and scientific decision-making. Adhering to compliance and ethical standards as the baseline, we operate with integrity to establish industry benchmarks. We are committed to building a comprehensive risk management system, driving long-term and stable corporate growth, and creating sustainable value for all stakeholders. Responsible Value ChainHitGen advances sustainable development across its entire value chain from supply, operations to client engagement by establishing sustainable supply chain system, industry-academia-research collaborative innovation networks, full-cycle quality control mechanisms, and robust data security safeguards, for the purpose of continuously building a resilient and responsible value ecosystem to fulfill its long-term commitment to human health. Harmonious Internal and External EcosystemHitGen takes social responsibility as its fundamental duty, demonstrating support through safeguarding employee rights and interests, creating an inclusive atmosphere with diversity and equality, empowering personal growth through training and development programs, protecting employee health and safety, and actively engaging in community contributions – all these actions exemplify the Company’s commitment to society. Eco-Conscious Environmental ManagementAdhering to the "Eco-Conscious, Planet-Responsible" philosophy, HitGen is dedicated in minimizing adverse impacts on the environment during R&D and operations, conserving natural resources, reducing greenhouse gas emissions, and protecting biodiversity and clean water sources. Dr. Jin Li said, "Guided by our value-creation-driven sustainability vision, we firmly believe our fundamental mission is to create value for society, value for development, and value for the future – thereby propelling technological innovation and business expansion. On this journey, we will persistently leverage market needs as our compass and technological breakthroughs as our engine, continuously optimizing our innovative drug R&D service system to build an ecosystem of positive reciprocity where patients benefit, the industry advances, employees grow, and all stakeholders achieve shared success." For more information on HitGen's Sustainability Report, please visit https://www.hitgen.com/en/sustainability.html 

  • Activity

    See you in Boston! HitGen to attend 2025 BIO International Convention

    From June 16th to 19th (US time), the 2025 BIO International Convention will take place at the Boston Convention & Exhibition Center in Massachusetts, USA. As the largest and most comprehensive event for biotechnology, the BIO International Convention represents the full ecosystem of biotech with 20,000 industry leaders from across the globe. HitGen Inc. looks forward to meeting you at Booth 1851. We also encourage scheduling meetings in advance through the BIO Partnering™ system to explore collaboration opportunities. 

Product&Services

OpenDEL™ Kit

Starting Your Journey to Access the Vast Chemical Space

The Kit

57 Libraries

~3.8Bn compounds

10 DEL samples

To Access

Fully enumerated molecules

Building Block Structures

DNA Codon Sequences

Scaffolds Information

No Structure Disclosure Fee

No Structure Disclosure Fee

Learn More more Quote more
case_01
OpenDEL™ Kit
01

OpenDEL™ Screening

OpenDEL™ screening is carried out by our team of experienced professionals, proficient in handling over 50 different target types including protein-protein interactions, kinases, enzymes, transcription factors, and RNA targets. Our team typically completes the screening experiments within 1-2 weeks. For more information and to explore detailed stories about our featured target types, click on the images below. We plan to release similar articles for other target classes in the future.
Learn More more Quote more
case_01
OpenDEL™ Screening
02

OpenDEL™ Sequencing

HitGen offers high-quality sequencing services powered by two Illumina platforms (NextSeq2000 and NovaSeq6000) and one MGI platform (MGISEQ-2000), supported by 8 versatile flow cell types. Our flexible solutions cover a wide range of sequencing capacities, from 400M to 10,000M reads, tailored to your specific needs. With an average Q30 score exceeding 92% and a turnaround time of under two days, we deliver both speed and reliability for your research. In addition to DNA-encoded library (DEL) sequencing, we also provide multi-omics sequencing and data analysis services.
Learn More more Quote more
case_01
OpenDEL™ Sequencing
03

OpenDEL™ Hit Proposal

Analyzing DEL selection data and choosing the right compounds for follow-up necessitates multidisciplinary expertise encompassing biology, computational science, and chemistry. This includes a deep understanding of the experimental design and mechanisms of action (MOAs) in biology, data processing and analysis in computational science, and aspects of both synthetic and DEL chemistry
Learn More more Quote more
case_01
OpenDEL™ Hit Proposal
04

OpenDEL™ Off-DNA Synthesis

Our traditional synthesis service excels at recreating complex chemical structures derived from various DELs. We offer diverse options, including traditional chemistry synthesis service and high-throughput synthesis service. 
A. Traditional Chemical Synthesis @ HitGen 
B. High Throughput Chemical Synthesis @ HitGen‘s

Learn More more Quote more
case_01
OpenDEL™ Off-DNA Synthesis
05

What are people in the community saying?

our clients feedback speaks volumes.discover their stories of success,collaboration,and the impactful results we ve delivered together

  • peijin
    peijin Li

    Product Manager

    DEL (DNA-encoded library) technology is transforming how we screen billions of compounds for new drugs—but is it truly a game-changer? What are its biggest breakthroughs, and where does it fall short? Could this be the future of pharmaceuticals, or are there still hurdles to overcome? Share your insights on the promises and challenges of DEL tech!

  • peijin
    peijin Li

    Product Manager

    DEL (DNA-encoded library) technology has revolutionized drug discovery by enabling rapid screening of billions of compounds. As it continues to evolve, what are its biggest potentials and limitations? How can it shape the future of pharmaceuticals? Share your thoughts on the advancements, applications, and ethical considerations surrounding DEL tech!

Resources

Messages and Feedback

By submitting your information, you acknowledge having received, read and understood our Privacy Notice as made available above.

logo
logo